A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso

BackgroundIn malaria-endemic countries, large proportions of infected individuals are asymptomatic, constituting a reservoir of parasites for infection of newly hatched mosquitoes. This study evaluated the impact of screening and treatment of asymptomatic carriers of Plasmodium falciparum.MethodsEighteen villages were randomized (1:1) to study arms and inhabitants participated in four community screening campaigns: three before the rainy season ~1 month apart, and the fourth after the rains at ~12 months. On day 1 of campaigns 1–3, asymptomatic carriers in the intervention arm were identified by rapid diagnostic test and treated with artemether-lumefantrine. Outcomes were symptomatic malaria with parasite density >5,000/μL per person-year in children <5 years and change in haemoglobin between days 1 and 28 of campaign 1.ResultsAt 12 months, the number of symptomatic malaria episodes with a parasite density >5,000/μL per person-year in children <5 years was not significantly different between arms (1.69 vs 1.60, p = 0.3482). Mean haemoglobin change in asymptomatic carriers during campaign 1 was greater in the intervention vs control arm (+0.53 g/dL vs -0.21 g/dL, p <0.0001). ANCOVA demonstrated that mean asymptomatic carriage at the cluster level was lower in the intervention vs control arm at day 1 of campaigns 2 (5.0% vs 34.9%, p <0.0001) and 3 (3.5% vs 31.5%, p <0.0001), but showed only a small difference at day 1 of campaign 4 (34.6% vs 37.6%, p = 0.2982). Mean gametocyte carriage was lower in the intervention vs control arm at day 1 of campaigns 2 and 3 (0.7% vs 5.4%, p <0.0001; 0.5% vs 5.8%, p <0.0001), but was similar at day 1 of campaign 4 (4.9% vs 5.1%, p = 0.7208).ConclusionsSystematic screening and treatment of asymptomatic carriers at the community level did not reduce clinical malaria incidence in the subsequent transmission season, indicating greater levels of parasite clearance are required to achieve a sustained impact in this setting.

[1]  Z. Premji,et al.  Treatment of asymptomatic carriers with artemether-lumefantrine: an opportunity to reduce the burden of malaria? , 2010, Malaria Journal.

[2]  Teun Bousema,et al.  Factors determining the occurrence of submicroscopic malaria infections and their relevance for control , 2012, Nature Communications.

[3]  V. Louis,et al.  Moving towards universal coverage with malaria control interventions: achievements and challenges in rural Burkina Faso. , 2013, The International journal of health planning and management.

[4]  C. Lengeler,et al.  Insecticide-treated bed nets and curtains for preventing malaria. , 2004, The Cochrane database of systematic reviews.

[5]  K. Marsh,et al.  What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity , 2009, Malaria Journal.

[6]  S. Cousens,et al.  Morbidity from Malaria in Children in the Year after They Had Received Intermittent Preventive Treatment of Malaria: A Randomised Trial , 2011, PloS one.

[7]  Teun Bousema,et al.  Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and Elimination , 2011, Clinical Microbiology Reviews.

[8]  Bernhards Ogutu,et al.  Community screening and treatment of asymptomatic carriers of Plasmodium falciparum with artemether-lumefantrine to reduce malaria disease burden: a modelling and simulation analysis , 2011, Malaria Journal.

[9]  O. Gaye,et al.  Long-term asymptomatic carriage of Plasmodium falciparum protects from malaria attacks: a prospective study among Senegalese children. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  André Garcia,et al.  Multiplicity of Plasmodium falciparum infection in asymptomatic children in Senegal: relation to transmission, age and erythrocyte variants , 2008, Malaria Journal.

[11]  K. Hamed,et al.  Transitioning from malaria control to elimination: the vital role of ACTs. , 2013, Trends in parasitology.

[12]  J. Aponte,et al.  A country-wide malaria survey in Mozambique. II. Malaria attributable proportion of fever and establishment of malaria case definition in children across different epidemiological settings , 2009, Malaria Journal.

[13]  S. Sirima,et al.  The effects of a pre‐season treatment with effective antimalarials on subsequent malaria morbidity in under five‐year‐old children living in high and seasonal malaria transmission area of Burkina Faso , 2010, Tropical medicine & international health : TM & IH.

[14]  N. Nanda,et al.  The complexities of malaria disease manifestations with a focus on asymptomatic malaria , 2012, Malaria Journal.

[15]  Z. Premji,et al.  Efficacy and Safety of Artemether-Lumefantrine in the Treatment of Acute, Uncomplicated Plasmodium falciparum Malaria: A Pooled Analysis , 2011, The American journal of tropical medicine and hygiene.

[16]  S. Lindsay,et al.  The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. , 2003, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[17]  Purnomo,et al.  Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis. , 1997, American Journal of Tropical Medicine and Hygiene.

[18]  Aniset Kamanga,et al.  A method of active case detection to target reservoirs of asymptomatic malaria and gametocyte carriers in a rural area in Southern Province, Zambia , 2010, Malaria Journal.

[19]  Weltgesundheitsorganisation World malaria report , 2005 .

[20]  T. Déirdre Hollingsworth,et al.  The Potential Contribution of Mass Treatment to the Control of Plasmodium falciparum Malaria , 2011, PloS one.

[21]  P. Milligan,et al.  Gametocytaemia after Drug Treatment of Asymptomatic Plasmodium falciparum , 2006, PLoS clinical trials.

[22]  T. Bousema,et al.  Adjusting for heterogeneity of malaria transmission in longitudinal studies. , 2011, The Journal of infectious diseases.

[23]  Svensson,et al.  Complexity of Plasmodium falciparum infections is consistent over time and protects against clinical disease in Tanzanian children. , 1999, The Journal of infectious diseases.